Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Wolbers

Showing results (21-30 of 135) with videos related to

Pageof 14
Sort By:
Epidemiology (Cambridge, Mass.)|April 16, 2009
Prognostic models with competing risks: methods and application to coronary risk predictionMarcel Wolbers, Michael T Koller, Jacqueline C M Witteman, et al.
AIDS (London, England)|July 17, 2007
Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphomaOlivier Gasser, Marcel Wolbers, Ingrid Steffen, et al.
Environmental Research|December 3, 2014
Sustained use of biogas fuel and blood pressure among women in rural NepalManiraj Neupane, Buddha Basnyat, Rainald Fischer, et al.
BMC Infectious Diseases|April 5, 2008
Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysisDominik Mertz, Nina Viktorin, Marcel Wolbers, et al.
Biostatistics (Oxford, England)|February 5, 2014
Concordance for prognostic models with competing risksMarcel Wolbers, Paul Blanche, Michael T Koller, et al.
Pharmaceutical Statistics|May 19, 2022
Standard and reference-based conditional mean imputationMarcel Wolbers, Alessandro Noci, Paul Delmar, et al.
Circulation|April 9, 2008
Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk studyMichael T Koller, Beat Schaer, Marcel Wolbers, et al.
European Heart Journal|April 9, 2014
Competing risks analyses: objectives and approachesMarcel Wolbers, Michael T Koller, Vianda S Stel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2022
Recurrent disability progression endpoints in multiple sclerosis clinical trialsAlexandra Bühler, Marcel Wolbers, Fabian Model, et al.
Trials|February 4, 2011
Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitisMarcel Wolbers, Dorothee Heemskerk, Tran Thi Hong Chau, et al.
Pageof 14

Showing results (21-30 of 135) with videos related to

Sort By:
Pageof 14
Epidemiology (Cambridge, Mass.)|April 16, 2009
Prognostic models with competing risks: methods and application to coronary risk predictionMarcel Wolbers, Michael T Koller, Jacqueline C M Witteman, et al.
AIDS (London, England)|July 17, 2007
Increased Epstein-Barr virus-specific antibody-levels in HIV-infected individuals developing primary central nervous system lymphomaOlivier Gasser, Marcel Wolbers, Ingrid Steffen, et al.
Environmental Research|December 3, 2014
Sustained use of biogas fuel and blood pressure among women in rural NepalManiraj Neupane, Buddha Basnyat, Rainald Fischer, et al.
BMC Infectious Diseases|April 5, 2008
Appropriateness of antibiotic treatment in intravenous drug users, a retrospective analysisDominik Mertz, Nina Viktorin, Marcel Wolbers, et al.
Biostatistics (Oxford, England)|February 5, 2014
Concordance for prognostic models with competing risksMarcel Wolbers, Paul Blanche, Michael T Koller, et al.
Pharmaceutical Statistics|May 19, 2022
Standard and reference-based conditional mean imputationMarcel Wolbers, Alessandro Noci, Paul Delmar, et al.
Circulation|April 9, 2008
Death without prior appropriate implantable cardioverter-defibrillator therapy: a competing risk studyMichael T Koller, Beat Schaer, Marcel Wolbers, et al.
European Heart Journal|April 9, 2014
Competing risks analyses: objectives and approachesMarcel Wolbers, Michael T Koller, Vianda S Stel, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 30, 2022
Recurrent disability progression endpoints in multiple sclerosis clinical trialsAlexandra Bühler, Marcel Wolbers, Fabian Model, et al.
Trials|February 4, 2011
Sample size requirements for separating out the effects of combination treatments: randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitisMarcel Wolbers, Dorothee Heemskerk, Tran Thi Hong Chau, et al.
Pageof 14